Last update : 07/22/2015 | Version : 2 | ID : 79
General | |
Identification | |
Detailed name | A European prospective observational study to evaluate fracture outcomes, back pain, health-related quality of life, and compliance in patients with osteoporosis during and after treatment with Forsteo® |
Sign or acronym | EXFOS |
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CNIL N°910339 |
General Aspects | |
Medical area |
Rheumatology |
Keywords | Osteoporotic patients, teriparatide, duration of treatment, conditions of use |
Scientific investigator(s) (Contact) | |
Name of the director | Médecin pharmacoépidémiologiste |
Fr_mail_pharmacoepi@lilly.com | |
Unit | Eli Lilly France |
Collaborations | |
Funding | |
Funding status |
Private |
Details | Eli Lilly and Company |
Governance of the database | |
Sponsor(s) or organisation(s) responsible | Eli Lilly |
Organisation status |
Private |
Additional contact | |
Main features | |
Type of database | |
Type of database |
Study databases |
Study databases (details) |
Longitudinal study (except cohorts) |
Database recruitment is carried out by an intermediary |
A selection of health care professionals |
Database recruitment is is made on the basis of: |
Medication(s) taken |
Database recruitment is carried out as part of an interventional study |
No |
Additional information regarding sample selection. | France: recruitment by rheumatologists in the course of routine care. Random selection of rheumatologists using professional listing. |
Database objective | |
Main objective |
Primary objective: determine the incidence of clinical vertebral fractures and non-vertebral fragility fractures in patients treated with teriparatide for about 18 months and a post-treatment follow-up period of at least 18 months.
Secondary objectives: observance, treatment switching and cessation, clinical evolution, occurrence of back pain, direct costs linked to fractures. |
Inclusion criteria | Osteoporotic patients initiating treatment with teriparatide according to the practitioner's opinion in routine care |
Population type | |
Age |
Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
Population covered |
Sick population |
Gender |
Male Woman |
Geography area |
International |
Detail of the geography area | Croatia, Denmark, France, Greece, Italy, Norway, Slovenia and Sweden |
Data collection | |
Dates | |
Date of first collection (YYYY or MM/YYYY) | 2006 |
Date of last collection (YYYY or MM/YYYY) | 2012 |
Size of the database | |
Size of the database (number of individuals) |
[500-1000[ individuals |
Details of the number of individuals | 1607 |
Data | |
Database activity |
Data collection completed |
Type of data collected |
Clinical data Declarative data |
Clinical data (detail) |
Direct physical measures Medical registration |
Declarative data (detail) |
Paper self-questionnaire |
Presence of a biobank |
No |
Health parameters studied |
Health event/morbidity Health care consumption and services Quality of life/health perception |
Care consumption (detail) |
Medicines consumption |
Procedures | |
Data collection method | Study data collection form |
Participant monitoring |
Yes |
Details on monitoring of participants | 36 months maximum |
Links to administrative sources |
No |
Promotion and access | |
Promotion | |
Link to the document | http://tinyurl.com/Pubmed-EXFOS |
Description | List of publications in Pubmed |
Access | |
Terms of data access (charter for data provision, format of data, availability delay) | Report and publication |
Access to aggregated data |
Access on specific project only |
Access to individual data |
Access on specific project only |
Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05